San Francisco, 06 May 2024: The Report Immunohistochemistry Market Size, Share & Trends Analysis Report By Product (Antibodies, Reagents, Kits), By Application (Diagnostics, Research), By End-use, By Region, And Segment Forecasts, 2023 - 2030

The global immunohistochemistry market size is expected to reach USD 3.50 billion by 2030, according to a new report by Grand View Research, Inc. The market is expected to register a CAGR of 5.8% from 2023 to 2030. The high demand for accurate data has driven several technological advancements in IHC techniques, resulting in the delivery of precise and contextual data analyses. The emergence of advanced techniques, such as multiplex IHC, computational pathology, and next-generation IHC, is driving the global market. Immunohistochemistry protocols have gained popularity in clinical pathology, especially in the subspecialties of oncologic pathology, hematopathology, and neuropathology.

The technique has played a vital role in shaping cancer diagnostics. Thus, the growing prevalence of cancer is expected to increase the demand for IHC, thus contributing to market growth. Furthermore, the wide application scope of IHC in drug discovery and development activities is expected to boost revenue growth over the forecast period. Whole slide imaging and digital image analysis offer highly accurate and objective evaluations. Thus, image analysis can be used across different aspects of drug discovery including drug repositioning, target validation, patient stratification, biomarker expression studies, and drug efficacy & safety studies.

Acknowledging the profitable opportunities posed by the space, operating players in the industry continue to undertake strategic initiatives to strengthen their market presence. For instance, in June 2021, PathAI, in collaboration with AstraZeneca and Daiichi Sankyo Company Ltd., created machine learning-based models to enable automated quantification of HER2 IHC images in breast cancer samples. The global market will benefit from the growing geriatric population in developed and developing nations. As the global geriatric population increases, the prevalence of age-related illnesses is predicted to rise drastically.

Increasing implementation of automation and machine learning in immunohistochemistry (IHC), coupled with the introduction of technologically advanced immunohistochemistry solutions, is expected to significantly drive the market throughout the forecast period. Advancements in IHC protocols have boosted its demand to a significant level in disease diagnosis. In addition, the rise in product approvals and the launch of technologically advanced immunohistochemistry systems for disease diagnosis are further propelling the market growth.

Request sample report of Immunohistochemistry Market@ https://www.grandviewresearch.com/industry-analysis/immunohistochemistry-ihc-market/request/rs1

For instance, in August 2021, the FDA approved Roche’s VENTANA MMR RxDx Panel to identify dMMR solid tumor patients eligible for anti-PD-1 immunotherapy. Companies continue to launch novel products to strengthen their market position, which leads to revenue generation. For instance, in March 2021, Roche launched the DISCOVERY Green HRP kit to detect and profile biomarkers and cell populations in tissue-based research. This kit can be utilized in combination with other detection kits, expanding the multiplexing capacity of in situ hybridization and immunohistochemistry. Similarly, in March 2023, Paige announced the inclusion of artificial intelligence (AI) algorithms of Mindpeak's for immunohistochemistry biomarker quantification on the company’s platform. Mindpeak, a software company specializing in image analysis, has contributed AI algorithms designed for the analysis of immunohistochemistry slides of lung and breast tissue, which are now available on the platform. IHC technology is limited to single parametric evaluations of a sample.

Immunohistochemistry Market Report Highlights

• The antibodies product segment led the market in 2022 owing to the high use of antibodies for immunohistochemistry assays carried out for disease diagnosis and drug testing workflows
• The diagnostics application segment led the market in 2022 owing to the widespread application of IHC tests in diagnostic settings
• The drug testing segment is expected to witness significant growth during the forecast period. This is due to increasing investment flow by pharmaceutical companies in R&D activities of novel drug discovery and development
• The hospitals and diagnostic laboratories end-use segment accounted for the largest revenue share in 2022. Research institutes are expected to register the fastest CAGR over the forecast period owing to the increasing adoption of IHC in research institutes for drug discovery activities
• North America emerged as the largest regional market in 2022 owing to the confluence of multiple factors, such as high cancer prevalence, presence of key players, and developed healthcare & biotechnological sectors
• The Asia Pacific is projected to grow at the fastest CAGR over the forecast period with China being the fastest-growing market. Increasing regulatory approvals and the launch of novel IHC solutions in China are accelerating the country’s market growth
• Key players are engaged in making focused attempts to reinforce their market position and gain a competitive advantage

Newer techniques such as multiplexed IHC, however, allow multiparametric and detailed analysis from a single tissue segment by utilizing advanced methods of mass spectrometric detection. Multiplexed IHC helps address the technical challenges posed by the labeled fluorescence detection-based method, thereby spurring the market revenue. The growing elderly population in both developed and emerging nations would favorably impact the Immunohistochemistry market. The frequency of age-related disorders is expected to rise dramatically as the global geriatric population grows significantly.RT-PCR, immunohistochemistry, and an electron microscope were used to detect the virus, indicating that the effect of SARS-CoV-2 is not limited to the lungs.

The antibodies segment dominated the market in 2022 and accounted for the largest share of 40.96% owing to the vital usage of antibodies in disease diagnosis and drug testing. The monoclonal antibodies and antibody-related products such as Fc-fusion, antibody fragments, and antibody-drug conjugates have become the dominating product class in terms of usage rate. The antibodies are applied across a wide range of applications such as pathology, neuropathology, and hematopathology.

Immunohistochemistry Market Report Scope

Kits are anticipated to expand at the fastest CAGR throughout the forecast period. The use of kits reduces a lot of efforts during the IHC procedure as it eliminates the selection procedure for use of an appropriate combination of antibodies and stains against a tissue sample. The compact nature and ease of use offered by the products under this segment are expected to drive the segment. IHC kits are commonly utilized in academic institutions and research laboratories that require these products in small quantities for carrying out research. Thus, rising research programs that involve the use of IHC assays are contributing to the segment growth.

List of Key Players in Immunohistochemistry Market

• Thermo Fisher Scientific Inc.
• F. Hoffmann-La Roche Ltd.
• Merck KGaA
• Danaher Corporation
• Perkinelmer, Inc.
• Bio-Rad Laboratories, Inc.
• Cell Signaling Technology, Inc.
• Bio SB
• Agilent Technologies, Inc.
• Abcam plc.